A recent review by Meyer et al.37highlights how IFN signaling in myeloid cells enhances anti-tumor immunity by inducing a pro-inflammatory phenotype, characterized among others by increased expression of CD80, CD40, and major histocompatibility complex class II (MHC class II) on macrophages, thereby promoting T cell activation and proliferation. The gene discussed is IFNA1; the disease is neoplasm.